Tenax Therapeutics, Inc. - Common Stock (TENX)

NEW YORK CITY, NY / ACCESS Newswire / October 30, 2026 / Levi & Korsinsky, LLP notifies investors in Tenax Therapeutics, Inc. (NASDAQ:TENX) that Stuart Rich, M.D., Tenax's Chief Medical Officer, is named as an individual defendant facing alleged liability in a securities class action filed on behalf of purchasers of Tenax securities between November 13, 2023 and August 7, 2026. Find out if you could qualify to recover your per-share losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

Investors who lost money on Tenax Therapeutics, Inc. ("Tenax" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Tenax Therapeutics, Inc. (NASDAQ: TENX) investors into whether the Company may have violated the federal securities laws. The investigation follows the August 10, 2026 disclosure regarding Tenax Therapeutics, Inc.

Investors who suffered losses on Tenax Therapeutics, Inc. ("Tenax" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Tenax Therapeutics, Inc. (NASDAQ: TENX) investors into whether the Company may have violated the federal securities laws. The investigation comes after a August 10, 2026 disclosure concerning Tenax Therapeutics, Inc.

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Tenax Therapeutics, Inc. (NASDAQ: TENX) securities between November 13, 2023 and August 7, 2026, inclusive (the “Class Period”), have until December 28, 2026 to seek appointment as lead plaintiff of the Tenax Therapeutics class action lawsuit. Captioned Katz v. Tenax Therapeutics, Inc., No. 26-cv-01264 (M.D.N.C.), the Tenax Therapeutics class action lawsuit charges Tenax Therapeutics and certain of Tenax Therapeutics’ top current and former executives with violations of the Securities Exchange Act of 1934.

NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) --

Tenax Therapeutics, Inc. ("Tenax" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in Tenax Therapeutics, Inc. (NASDAQ: TENX), examining whether the Company may have violated the federal securities laws. The investigation centers on the disclosure about Tenax Therapeutics, Inc. on August 10, 2026.

Rosen Law Firm, a global investor rights law firm, announces a class action on behalf of purchasers of securities of Tenax Therapeutics, Inc. (NASDAQ: TENX) between November 13, 2023 and August 7, 2026, inclusive (the “Class Period”). Tenax is a Phase 3, development stage pharmaceutical company.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) and certain officers.   The class action, filed in the United States District Court for the Middle District of North Carolina, and docketed under 26-cv-01624, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Tenax securities between November 13, 2023 and August 7, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Tenax Therapeutics, Inc. (NASDAQ: TENX) securities between November 13, 2023 and August 7, 2026, inclusive (the “Class Period”). Tenax is a development-stage pharmaceutical company focused on novel cardiopulmonary therapies.

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tenax Therapeutics, Inc. (“Tenax” or “the Company”) (NASDAQ: TENX) for violations of the securities laws.

A single clinical readout drove Tenax Therapeutics (NASDAQ: TENX) shares down approximately 84% to 85% shareholder after the Company disclosed that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both its primary and key secondary endpoints. If you held TENX shares and suffered a loss, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

Tenax Therapeutics, Inc. (NASDAQ: TENX) is one of today’s top gainers. The company’s shares have moved 82.38% on the day to $15.94.

Tenax Therapeutics (NASDAQ: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced the pricing of a public offering of 8,666,666 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 17,333,332 shares of its common stock at a purchase price of $1.80 per share and associated public warrant. According to the announcement, the public warrants will have an exercise price of $2.25 per share, are immediately exercisable and will expire five years after their initial exercise date. Roth Capital Partners acted as sole placement agent for the offering, which closed on Feb. 7, 2023.

Tenax Therapeutics, Inc. (NASDAQ: TENX) is engaged as a specialty pharmaceutical company, which is focused on the research, development and

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will host a key opinion leader (KOL) webinar about TNX-201 (oral, modified release imatinib), in development as a potential treatment for pulmonary arterial hypertension (PAH), on Thursday, June 2, 2022 at 11:00am Eastern Time.

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced the successful completion of its comparative pharmacokinetic study of TNX-201, for the treatment of pulmonary arterial hypertension (“PAH”).

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of 10,596,027 Units at a purchase price of $0.755 per Unit. Each Unit consists of one unregistered pre-funded warrant to purchase one share of the Company’s common stock, par value $0.0001, and one unregistered warrant to purchase one share of the Company’s common stock. In the aggregate, 21,192,054 shares of the Company’s common stock are underlying the warrants. The offering is expected to close on or about May 19, 2022, subject to the satisfaction of customary closing conditions.

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the year ended December 31, 2021 and provided a business update.

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that two presentations will be made at the upcoming American College of Cardiology (ACC) Scientific Sessions featuring the Company’s lead drug candidates, imatinib and levosimendan, both of which are currently in late-stage development for the treatment of pulmonary hypertension. The ACC’s annual meeting is being held on April 2-4, 2022, in Washington, D.C.

San Diego, CA -- (SBWIRE) -- 02/17/2022 -- Certain directors of Tenax Therapeutics, Inc. are under investigation concerning potential breaches of fiduciary duties .

San Diego, CA -- (SBWIRE) -- 12/13/2021 -- An investigation was announced for investors of Tenax Therapeutics, Inc. (NASDAQ:TENX) shares over potential securities laws violations by Tenax Therapeutics, Inc.

San Diego, CA -- (SBWIRE) -- 12/01/2021 -- Certain directors of Tenax Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties.

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the third quarter of 2021 and provided a business update.

San Diego, CA -- (SBWIRE) -- 11/09/2021 -- Tenax Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, today announced that the FDA has reviewed and cleared its Investigational New Drug (IND) application for a novel formulation of imatinib. Tenax intends to initiate in October, and complete before the end of 2021, a comparative pharmacokinetic (PK) study, bridging to the start of a Phase 3 trial of their delayed-release formulation for the treatment of pulmonary arterial hypertension (PAH).